Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents
Endocrinology and Metabolism Clinics of North America · 2026-09 · 55 (3) · 547-561
DOI: 10.1016/j.ecl.2026.04.009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2026-09. Verfasst von Husam Ghanim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, State University of NY at Buffalo, 1000 Youngs Road, Suite 105, Buffalo, …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 54 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Even with the most advanced insulin preparations and delivery systems currently available, it is challenging for many people with type 1 diabetes (T1D) to achieve target levels of glycemic management. Adjunct therapy in T1D consists of adding glucose-lowering agents besides insulin with the aim of lowering hemoglobin A1c (HbA1c) and improving other health outcomes, including weight. It is an attractive potential strategy for achieving glycemic targets and other benefits in this T1D subpopulation. While not yet Food and Drug Adminstration (FDA)-approved for this use, incretin-based therapies (glucagon-like peptide-1 receptor agonist-based therapy) and sodium-glucose cotransporter-1/2 (SGLT-1/2) inhibitors are being prescribed off-label for T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, State University of NY at Buffalo, 1000 Youngs Road, Suite 105, Buffalo, NY 14221, USA. Electronic address: ghanim@buffalo.edu.
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, State University of NY at Buffalo, 1000 Youngs Road, Suite 105, Buffalo, NY 14221, USA.
Zitieren
APA
Ghanim, H., Srungavarapu, S. R., Dandona, P., & Chaudhuri, A. (2026). Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents. Endocrinology and Metabolism Clinics of North America, 55(3), 547-561. https://doi.org/10.1016/j.ecl.2026.04.009
Vancouver
Ghanim H, Srungavarapu SR, Dandona P, Chaudhuri A. Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents. Endocrinology and Metabolism Clinics of North America. 2026;55(3):547-561. doi:10.1016/j.ecl.2026.04.009
BibTeX
@article{Ghanim2026,
author = {Ghanim, Husam and Srungavarapu, Sambasiva Rao and Dandona, Paresh and Chaudhuri, Ajay},
title = {Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents},
journal = {Endocrinology and Metabolism Clinics of North America},
year = {2026},
volume = {55},
number = {3},
pages = {547--561},
doi = {10.1016/j.ecl.2026.04.009}
}
EUVIMED